RBC Capital raised the firm’s price target on Pharming (PHAR) to EUR 2.45 from EUR 2 and keeps an Outperform rating on the shares.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHAR:
- Pharming price target raised to $41 from $40 at Oppenheimer
- Pharming Group’s Strong Financial Performance and Strategic Developments Justify Buy Rating
- Pharming Group Reports Strong Q2 2025 Revenue Growth
- Pharming Group Reports Strong Q2 2025 Financial Results and Business Update
- Pharming Group’s Growth Potential Boosted by Advances in APDS Diagnosis and Treatment